BACKGROUND Platelet activating factor PAF seems to be implicated in systemic lupus erythematosus SLE patients with associated renal diseases Aims In this study we ensured the role of PAF in SLE patients without renal complications Methods Blood PAF and acetylhydrolase activity plasma soluble phospholipase A2 and the presence of antibodies against PAF were investigated in SLE patients without active nephritis and in healthy controls Results Blood PAF levels were not different p between SLE patients pg ml and healthy subjects pg ml Plasma acetylhy drolase activity the PAF degrading enzyme was significantly p elevated in SLE patients nmol min ml as compared with controls nmol min ml Plasma soluble phospholi pase A2 the key enzyme for PAF formation was not different p between SLE patients U ml and controls U ml Antibodies against PAF were detected only in SLE patients Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients Conclusion This clinical study highlights no evi dence for a putative important role of PAF in SLE patients without active nephritis

Yves Denizot1

Description

Niveau: Secondaire, Lycée, Terminale
UN CO RR EC TE D P RO OF BACKGROUND : Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases. Aims : In this study, we ensured the role of PAF in SLE patients without renal complications. Methods : Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A2, and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls. Results : Blood PAF levels were not different (p/ 0.45) between SLE patients (6.79/2.8 pg/ml) and healthy subjects (9.69/3.1 pg/ml). Plasma acetylhy- drolase activity (the PAF-degrading enzyme) was significantly (p/0.03) elevated in SLE patients (57.89/6.4 nmol/min/ml) as compared with controls (37.99/2.6 nmol/min/ml). Plasma soluble phospholi- pase A2 (the key enzyme for PAF formation) was not different (p/0.6) between SLE patients (59.19/5.1 U/ ml) and controls (54.79/2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients. Conclusion : This clinical study highlights no evi- dence for a putative important role of PAF in SLE patients without active nephritis.

• human reprod


• aha levels


• differences between


• blood paf


• anti


• plasma soluble


• lupus erythematosus


• platelet-activating factor


• systemic lupus


• elevated plasma

Sujets

• Première
• Bombardier
• Shimizu
• Antibodies

Informations

• Publié par: profil-zyan-2012
• Nombre de lectures: 11
• Langue: English

Extrait

Y:/Taylor & Francis/cMIN/Articles/cmin031005/CMIN031005.3d[x]

Research Communication

B ACKGROUND : Plateletactivating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases. Aims: In this study, we ensured the role of PAF in SLE patients without renal complications. Methods: Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A 2 , and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls. Results: Blood PAF levels were not different (p / 0.45) between SLE patients (6.792.8 pg/ml) and / healthy subjects (9.693.1 pg/ml). Plasma acetylhy / drolase activity (the PAFdegrading enzyme) was significantly (p0.03) elevated in SLE patients / (57.896.4 nmol/min/ml) as compared with controls / (37.992.6 nmol/min/ml). Plasma soluble phospholi / pase A 2 (the key enzyme for PAF formation) was not different (p0.6) between SLE patients (59.195.1 U/ / / ml) and controls (54.792.4 U/ml). Antibodies against / PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients. Conclusion: This clinical study highlights no evi dence for a putative important role of PAF in SLE patients without active nephritis.

Key words:Acetylhydrolase activity, Plateletactivating factor, Soluble phospholipase A 2 , Systemic lupus erythe matosus

Monday, 14th April 200315:1:46

Mediators of Inflammation,12, 101105 (2003) /

No evidence for a putative involvement of plateletactivating factor in systemic lupus erythematosus without active nephritis

1,CA 21 Yves Denizot, EricLiozon , Laurence Guglielmi , 2 22 KimLy,PascaleSoria,V´eroniqueLoustaud, 2 1 Elisabeth Vidaland Marie OdileJauberteau

1 UMR CNRS 6101, Laboratoire d’Immunologie, Faculte´ deMe´ decine,2 rue Dr Marcland, 87025 2 Limoges,France;ServicedeM´edecineInterne,CHU Dupuytren, Limoges France

CA Corresponding Author Tel:33 5 55 43 58 96 / Fax:33 5 55 43 58 97 / Email: [e-mail]

9,10 lymphocytes. Elevatedplasma PAF levels are Introduction reported during the most active phases of the 11 Plateletactivating factor (PAF) is a phospholipid disease, andmonocytes from active SLE patients compound produced by stimulated inflammatory produce higher levels of PAF compared with inactive 12 cells such as monocytes, neutrophils, and eosino patients and controls.AHA levels are also affected 1 phils. PAFis not stored in cells, but is derived from a in human SLE. Thus, studies report either reduced or membrane precursor, 1alkyl2acylglycero3phos elevated AHA levels in SLE patients as compared with 11,13 healthy controls.SLE is often characterised by the phocholine. The action of a phospholipase A 2  dependent process generates the lysoPAF, and the development of immune complex glomerulonephri subsequent acetylation of the lyso compound results tis; lupus nephritis being a leading cause of morbidity 14 1 in the PAF molecule.PAF concentrations are regu and mortality in SLE.Since the PAF/AHA couple is 58 lated by an acetylhydrolase activity (AHA) found both deregulated during renal diseases,it is difficult to 2,3 in plasma and serum.PAF acts through proteinG state whether PAF may be defined as a pathogenic coupled PAF receptors (PAFR) present on the mediator in SLE or is only the reflection of the 4 membrane of responsive cells.PAF sparks a wide presence of associated diseases, especially renal range of inflammatory actions on various cells and ones. Moreover, if abnormal serum lipid profiles are 5,6 organs including the kidneys.Thus, elevated blood common in patients with active SLE, they are absent 15 PAF levels are reported in patients with glomerulone in SLE patients without renal diseases.In this study, 7 phritis andidiopathic immunoglobulin (Ig)A ne we investigated blood PAF levels and plasma AHA in 8 phropathy. SLEpatients without active nephritis. We also as Studies suggest that PAF may play a role in sessed their plasma soluble phospholipase A 2 (sPLA 2 ) systemic lupus erythematosus (SLE) patients. Thus, levels, the presence of antibodies against PAF and the PAF enhances immunoglobulin production by B presence of PAFR on their peripheral blood cells. ISSN 09629351 print/ISSN 14661861 online/03/02010105–2003 Taylor & Francis Ltd101 DOI: 10.1080/0962935031000097718